Northeast Pharmaceutical's wholly-owned subsidiary, Northeast Pharmaceutical Group Shenyang No. 1 Pharmaceutical Co., Ltd., has received the drug registration certificate for Pregabalin Capsules approved and issued by the National Medical Products Administration, covering two specifications of 75 mg and 150 mg. The drug is used for the treatment of postherpetic neuralgia, fibromyalgia, and as adjunctive therapy for partial-onset seizures in adults. The company stated that this approval helps enrich its product pipeline and enhance market competitiveness.
Northeast Pharmaceutical Group Co LtdSubsidiary obtained drug registration certificate for Pregabalin Capsules, enabling market entry.